Core Viewpoint - The company Boan Biotech (06955.HK) has received approval from the National Medical Products Administration for its self-developed product, Boyouping® (Dulaglutide Injection), aimed at blood sugar control in adult patients with type 2 diabetes. This product is the world's first and currently the only approved biosimilar to Trulicity® and is the only domestic dulaglutide injection that has not entered the Biologics License Application (BLA) stage in China [1]. Group 1 - Boan Biotech's Boyouping® is the first and only approved biosimilar to Trulicity® globally [1] - The product is specifically designed for blood sugar control in adult type 2 diabetes patients [1] - The commercialization of Boyouping® in mainland China will be conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd [1]
博安生物(06955.HK)：度拉糖肽注射液博优平®在中国获批上市